Research centers in six countries will work on metabolome-related global health challenges including autism, cancer, diabetes, dementia, and obesity.
In addition to Illumina and Thermo Fisher, the investment bank reinitiated coverage of Bruker, Invitae, Agilent, Waters, and T2 Biosystems.
Posting strong pharma sales but weakness in academia and government, Waters matched analysts' average EPS estimate for the quarter but fell short on revenues.
Among the launches at the organization's annual meeting this week in Taipei were a personalized proteomics initiative and a new DIA mass spec method.
The company posted Q2 revenues of $536.6 million, up from $494.7 million in Q2 2015 and beating the average Wall Street estimate of $523.4 million.
The mass spectrometry instrument maker will provide A*Star's Bioprocessing Technology Institute with expertise and access to a Synapt G2-S instrument.
While most firms launched new mass spec systems, the larger focus was on developing and implementing the larger workflows surrounding these instruments.
Along with scientists from the University of Leicester, the researchers picked the Xevo TQ-S micro platform to do a pilot study on heart failure patient samples.
The firm sold three series of senior notes and will use proceeds to repay other outstanding debt.
Driven by strong pharma demand, the company posted first quarter revenues of $475.2 million, beating the average Wall Street estimate of $472.2 million.
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.